nach oben

Discover Oncology

Erschienen in:

01.02.2010

Circulating Sex Steroids and Breast Cancer Risk in Premenopausal Women

verfasst von: Susan E. Hankinson, A. Heather Eliassen

Erschienen in: Discover Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Evidence from both laboratory and epidemiologic studies indicate a key role of hormones in the etiology of breast cancer. In epidemiologic studies, indirect data, including the consistent associations observed between reproductive factors and breast cancer risk, support an important contribution of hormones to risk. Recently, the associations between circulating hormones in premenopausal women and subsequent risk of breast cancer have been evaluated. To date, both positive and null associations have been observed for estrogens and inverse and null associations for progesterone with breast cancer risk. For estrogens, the relationships may vary by menstrual cycle phase (e.g., follicular versus luteal phase), although this requires confirmation. Few studies have evaluated estrogen metabolites in relation to breast cancer risk; hence, no conclusions can yet be drawn. Findings for the largely adrenal-derived dehydroepiandrosterone (DHEA) and DHEA sulfate also are inconsistent and may vary by age. However, relatively consistent positive associations have been observed between testosterone (or free testosterone) levels and breast cancer risk; these associations are of similar magnitude to those confirmed among postmenopausal women. In this review, we summarize current evidence and identify gaps and inconsistencies that need to be addressed in future studies of sex steroids and premenopausal breast cancer risk.

Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12(4):1071–1082CrossRefPubMed

Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96(24):1856–1865PubMed

Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616

Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6(5):213–218CrossRefPubMed

Liao DJ, Dickson RB (2002) Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 80(2):175–189CrossRefPubMed

Dickson RB, Stancel GM (2000) Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 27:135–145PubMed

King RJ (1993) William L. McGuire memorial symposium. Estrogen and progestin effects in human breast carcinogenesis. Breast Cancer Res Treat 27(1-2):3–15CrossRefPubMed

de Waard F, Thijssen JH (2005) Hormonal aspects in the causation of human breast cancer: epidemiological hypotheses reviewed, with special reference to nutritional status and first pregnancy. J Steroid Biochem Mol Biol 97(5):451–458CrossRefPubMed

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354):296–300CrossRefPubMed

10.

Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235–3258, PMCID: PMC2716943CrossRefPubMed

11.

Rabaglio M, Aebi S, Castiglione-Gertsch M (2007) Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 8(10):940–949CrossRefPubMed

12.

Muti P, Trevisan M, Micheli A, Krogh V, Bolelli G, Sciajno R, Berrino F (1996) Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 5(11):917–922PubMed

13.

Micheli A, Muti P, Pisani P, Secreto G, Recchione C, Totis A, Fissi R, Cavalleri A, Panico S, Berrino F (1991) Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women. J Clin Epidemiol 44(10):1055–1061CrossRefPubMed

14.

Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE (2006) Reproductibility of plasma hormone and growth factor levels among premenopausal women over a 2–3 year period. Cancer Epidemiol Biomarkers Prev 15(5):972–978CrossRefPubMed

15.

Michaud DS, Manson JE, Spiegelman D, Barbieri RL, Sepkovic DW, Bradlow HL, Hankinson SE (1999) Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 8(12):1059–1064PubMed

16.

Willett WC (1998) Nutritional epidemiology, 2nd edn. Oxford University Press, New York

17.

Rosner B, Spiegelman D, Willett WC (1992) Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 136(11):1400–1413PubMed

18.

Mady EA, Ramadan EE, Ossman AA (2000) Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers 16(3–4):151–157PubMed

19.

Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1–3):31–41CrossRefPubMed

20.

Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21(3):427–433CrossRefPubMed

21.

Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203–232CrossRefPubMed

22.

Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270–282CrossRefPubMed

23.

Van Aswegen CH, Purdy RH, Wittliff JL (1989) Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem 32(4):485–492CrossRefPubMed

24.

Anstead GM, Carlson KE, Katzenellenbogen JA (1997) The estradiol pharmacophore: ligand structure–estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62(3):268–303CrossRefPubMed

25.

Barnea ER, MacLusky NJ, Naftolin F (1983) Kinetics of catechol estrogen–estrogen receptor dissociation: a possible factor underlying differences in catechol estrogen biological activity. Steroids 41(5):643–656CrossRefPubMed

26.

Miyairi S, Ichikawa T, Nambara T (1991) Structure of the adduct of 16 alpha-hydroxyestrone with a primary amine: evidence for the Heyns rearrangement of steroidal d-ring alpha-hydroxyimines. Steroids 56(7):361–366CrossRefPubMed

27.

Bucala R, Fishman J, Cerami A (1982) Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc Natl Acad Sci USA 79(10):3320–3324CrossRefPubMed

28.

Swaneck GE, Fishman J (1988) Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 85(21):7831–7835CrossRefPubMed

29.

Lustig RH, Mobbs CV, Pfaff DW, Fishman J (1989) Temporal actions of 16 alpha-hydroxyestrone in the rat: comparisons of lordosis dynamics with other estrogen metabolites and between sexes. J Steroid Biochem 33(3):417–421CrossRefPubMed

30.

Seeger H, Wallwiener D, Kraemer E, Mueck AO (2005) Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 54:72–77CrossRefPubMed

31.

Gupta M, McDougal A, Safe S (1998) Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol 67(5–6):413–419CrossRefPubMed

32.

Schneider J, Huh MM, Bradlow HL, Fishman J (1984) Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259(8):4840–4845PubMed

33.

Vandewalle B, Lefebvre J (1989) Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 61(2):239–246CrossRefPubMed

34.

Mueck AO, Seeger H, Lippert TH (2002) Estradiol metabolism and malignant disease. Maturitas 43(1):1–10CrossRefPubMed

35.

Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG (1997) Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94(20):10937–10942CrossRefPubMed

36.

Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL (1996) Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 9(5):851–859CrossRefPubMed

37.

Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86(3–5):477–486CrossRefPubMed

38.

Devanesan P, Todorovic R, Zhao J, Gross ML, Rogan EG, Cavalieri EL (2001) Catechol estrogen conjugates and DNA adducts in the kidney of male Syrian golden hamsters treated with 4-hydroxyestradiol: potential biomarkers for estrogen-initiated cancer. Carcinogenesis 22(3):489–497CrossRefPubMed

39.

Chakravarti D, Mailander PC, Li KM, Higginbotham S, Zhang HL, Gross ML, Meza JL, Cavalieri EL, Rogan EG (2001) Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 20(55):7945–7953CrossRefPubMed

40.

Cavalieri EL, Kumar S, Todorovic R, Higginbotham S, Badawi AF, Rogan EG (2001) Imbalance of estrogen homeostasis in kidney and liver of hamsters treated with estradiol: implications for estrogen-induced initiation of renal tumors. Chem Res Toxicol 14(8):1041–1050CrossRefPubMed

41.

Wysowski DK, Comstock GW, Helsing KJ, Lau HL (1987) Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 125(5):791–799PubMed

42.

Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW (1994) A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 18(2):79–85PubMed

43.

Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE (2000) A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 9(6):575–579PubMed

44.

Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 75(7):1075–1079PubMed

45.

Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG (1994) Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 140(6):518–525PubMed

46.

Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjonneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97(10):755–765PubMed

47.

Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406–1415PubMedCrossRef

48.

Siiteri PK (1981) Extraglandular oestrogen formation and serum binding of oestradiol: relationship to cancer. J Endocrinol 89(Suppl):119P–129PPubMed

49.

Siiteri PK, MacDonald PC (1973) The role of extraglandular estrogen in human endocrinology. In: Geiger SR, Astwood EB, Greep RO (eds) Handbook of physiology: section 7-Endocrinology 615–629. American Physiological Society, New York

50.

Santoro N, Lasley B, McConnell D, Allsworth J, Crawford S, Gold EB, Finkelstein JS, Greendale GA, Kelsey J, Korenman S, Luborsky JL, Matthews K, Midgley R, Powell L, Sabatine J, Schocken M, Sowers MF, Weiss G (2004) Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: the Study of Women's Health across the Nation (SWAN) Daily Hormone Study. J Clin Endocrinol Metab 89(6):2622–2631CrossRefPubMed

51.

Landgren BM, Collins A, Csemiczky G, Burger HG, Baksheev L, Robertson DM (2004) Menopause transition: annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab 89(6):2763–2769CrossRefPubMed

52.

Yue W, Santner SJ, Masamura S, Wang JP, Demers LM, Hamilton C, Santen RJ (1998) Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 49(Suppl 1):S1–S7, discussion S33-7CrossRefPubMed

53.

Masamura S, Santner SJ, Gimotty P, George J, Santen RJ (1997) Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res Treat 42(3):215–226CrossRefPubMed

54.

Stute P, Wood CE, Kaplan JR, Cline JM (2004) Cyclic changes in the mammary gland of cynomolgus macaques. Fertil Steril 82(Suppl 3):1160–1170CrossRefPubMed

55.

Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH (1998) Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 78(9):1250–1255PubMed

56.

Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F (2000) Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16 alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11(6):635–640CrossRefPubMed

57.

Arslan AA, Shore RE, Afanasyeva Y, Koenig KL, Toniolo P, Zeleniuch-Jacquotte A (2009) Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 18(8):2273–2279CrossRefPubMed

58.

Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, Saavedra JE, Keefer LK, Ziegler RG (2005) Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 77(20):6646–6654CrossRefPubMed

59.

Falk RT, Xu X, Keefer L, Veenstra TD, Ziegler RG (2008) A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev 17(12):3411–3418CrossRefPubMed

60.

Eliassen HA, Ziegler RG, Rosner B, Veenstra TD, Roman JM, Xu X, Hankinson SE (2009) Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 18(11):2860CrossRefPubMed

61.

Ebeling P, Koivisto VA (1994) Physiological importance of dehydroepiandrosterone. Lancet 343(8911):1479–1481CrossRefPubMed

62.

Seymour-Munn K, Adams J (1983) Estrogenic effects of 5-androstene-3 beta, 17 beta-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology 112(2):486–491CrossRefPubMed

63.

Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F (2004) Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 112(2):312–318CrossRefPubMed

64.

Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P (2004) Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 90(1):153–159CrossRefPubMed

65.

Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW (1992) Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 52(1):1–4PubMed

66.

Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC, Hankinson SE (2004) Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 13(6):1032–1036PubMed

67.

Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE (2006) The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 15(5):967–971CrossRefPubMed

68.

Mauvais-Jarvis P, Kuttenn F, Gompel A (1987) Antiestrogen action of progesterone in breast tissue. Horm Res 28(2–4):212–218CrossRefPubMed

69.

Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10(2):179–186CrossRefPubMed

70.

Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17–35PubMed

71.

Lanari C, Molinolo AA (2002) Progesterone receptors–animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res 4(6):240–243CrossRefPubMed

72.

Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F (2005) Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 96(2):95–108CrossRefPubMed

73.

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350(9084):1047–1059CrossRef

74.

Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101(7):1490–1500CrossRefPubMed

75.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRefPubMed

76.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289(24):3243–3253CrossRefPubMed

Titel: Circulating Sex Steroids and Breast Cancer Risk in Premenopausal Women
verfasst von: Susan E. Hankinson
A. Heather Eliassen
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: Discover Oncology / Ausgabe 1/2010
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-009-0003-0

Springer Medizin

Circulating Sex Steroids and Breast Cancer Risk in Premenopausal Women

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Mouse Prostate Cancer Cell Lines Established from Primary and Postcastration Recurrent Tumors

Estrogen-Induced Aurora Kinase-A (AURKA) Gene Expression is Activated by GATA-3 in Estrogen Receptor-Positive Breast Cancer Cells

Trends in Distant-Stage Breast, Colorectal, and Prostate Cancer Incidence Rates from 1992 to 2004: Potential Influences of Screening and Hormonal Factors

Letter from the Editor-in-Chief

Specific Overexpression of Cyclin E·CDK2 in Early Preinvasive and Primary Breast Tumors in Female ACI Rats Induced by Estrogen

Quantitative Immunohistochemical Analysis and Prognostic Significance of TRPS-1, a New GATA Transcription Factor Family Member, in Breast Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie